Fundraising Fox
Cardax
Honolulu, US · Founded 2012 · Delaware corporation
Find your way into Cardax
Sign up to see every warm intro you have to Cardax
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cardax team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cardax is a consumer health company that markets ZanthoSyn, a physician-recommended astaxanthin dietary supplement aimed at inflammatory health. The company previously developed pharmaceuticals for inflammation-driven diseases and holds pre-clinical candidates for cardiovascular inflammation/dyslipidemia (CDX-101) and macular degeneration (CDX-301).
Founders & leadership
Cardax was founded in 2012 by David G. Watumull and David M. Watumull.
DG
David G. WatumullCo-founder
DM
David M. WatumullCo-founder
NM
Nicholas MitsakosExecutive Chairman, Investor2004–2020Nicholas Mitsakos is Chairman and CEO of Arcadia Capital, a firm managing investments in public securities and venture capital. He holds an MBA from Harvard Business School and advanced degrees in computer science and global policy from MIT and Harvard Kennedy School, and has served as investor and advisor to multiple technology and financial services companies.
JB
John B. RussellExecutive
Board
TA
Terence A. KellyBoard director
GW
George W. Bickerstaff IIIBoard director
FH
Frank HerringerBoard director
Reported raises · per SEC filings
Form D private placements$7.3M disclosed across 4 rounds · 2014–2021
▶$200KraisedSep 2021 · 5 investors · PharmaceuticalsRule 506(b)
▶$200KraisedSep 2021 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David G. WatumullExecutive Officer, Director
- David M. WatumullExecutive Officer
- Offering amount
- $500K
- Amount sold
- $200K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2017 · 50 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMay 2017 · 50 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John B. RussellExecutive Officer
- David G. WatumullExecutive Officer, Director
- Michele GalenDirector
- George W. Bickerstaff IIIDirector
- Terence A. KellyDirector
- Amount sold
- $1.5M
- Minimum investment
- $10K
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedNov 2015 · 29 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedNov 2015 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David G. WatumullExecutive Officer, Director
- Nicholas MitsakosExecutive Officer, Director
- Terence A. KellyDirector
- George W. Bickerstaff IIIDirector
- John B. RussellExecutive Officer
- Offering amount
- $4M
- Amount sold
- $1.6M
- Minimum investment
- $10K
- Sales commissions
- $28.6K
- Placement agents
- Andrew Garrett, Inc.
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$3.9MraisedFeb 2014 · 62 investors · PharmaceuticalsRule 506(b)
▶$3.9MraisedFeb 2014 · 62 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M. WatumullExecutive Officer
- David G. WatumullExecutive Officer, Director
- Frank HerringerDirector
- John RussellExecutive Officer
- Nicholas MitsakosDirector
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- Minimum investment
- $5K
- Sales commissions
- $530K
- Proceeds to insiders
- $55K
- Placement agents
- Portfolio Advisors Alliance, Inc., Agincourt Ltd.
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
CyanotechCyanotech cultivates Hawaiian microalgae to produce products for health and nutrition, operating from a farm in Kailua-Kona with 90 acres of cultivation ponds since 1984. The company focuses on sustainable, environmentally sensitive production of microalgae-based nutritional products.
NutraceuticalbusinessreviewADM is expanding its natural food colour production capabilities at its Kentucky facility to serve food and beverage manufacturers transitioning away from synthetic colorants due to regulatory pressure and consumer preference shifts. The expansion will increase capacity for liquid and dry-blended color solutions derived from natural sources.
Companies working in the same space as Cardax.
In the news
Frequently asked questions
- What does Cardax do?
- Cardax is a consumer health company that markets ZanthoSyn, a physician-recommended astaxanthin dietary supplement aimed at inflammatory health. The company previously developed pharmaceuticals for inflammation-driven diseases and holds pre-clinical candidates for cardiovascular inflammation/dyslipidemia (CDX-101) and macular degeneration (CDX-301).
- Who founded Cardax?
- Cardax was founded by David G. Watumull, David M. Watumull in 2012.
- How much funding has Cardax raised?
- Cardax has disclosed $7.3M raised across 4 rounds.
- Where is Cardax headquartered?
- Cardax is headquartered in Honolulu, US.